Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Clinical evidence

COMP004

36 evidence topics · 9 sources

Objective
Location and study date
Study dates and identifiers
ItemRegistry record
Other study ID“COMP004”
Study start (actual)“2020-07-20”
Primary completion (actual)“2022-08-11”
Study completion (actual)“2022-08-11”
Last update posted“2022-09-22”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using time to depressive event as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment: registry record
Enrollment typeParticipants
Actual“66”
Planned enrollment

No evidence found.

Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary: observational design, selected subgroup, few events, post hoc analysis

COMP004 was an observational follow-up that enrolled 66 participants who had completed COMP001 or COMP003, 58 of them from COMP001. The prespecified primary analysis covered all COMP001 participants, and the analysis restricted to enrolled participants was post hoc and based on 10 depressive events after enrollment. At entry, more participants in the 1 mg group were taking antidepressant medication (10, compared with 9 in the 10 mg and 6 in the 25 mg group). The published and Form 10-K medians for the 10 mg group differ (83 and 86 days). The authors state that larger long-term studies are required, and FDA guidance describes blinded long-term follow-up with prespecified retreatment criteria as the most informative design.